SCHEMBL9924924

SCHEMBL9924924

CCCCOc1ccc(-c2ccc(C3CCC4CC(COc5ccc(OCC)c(F)c5F)CCC4C3)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.43
CYP2D6 P10635 4/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 3/20 0.34
HRH3 Q9Y5N1 1/20 0.34
CYP1A2 P05177 3/20 0.33
CYP2C19 P33261 3/20 0.33
RARB P10826 2/20 0.33
NPC1 O15118 2/20 0.33
SCN9A Q15858 1/20 0.33
CRBN Q96SW2 1/20 0.33
RARA P10276 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
S1PR3 Q99500 1/20 0.33
KDM1A O60341 2/20 0.33
CYP19A1 P11511 2/20 0.33
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924790 0.97 RAB9A (0.45) RAB9ACYP2D6CYP3A4CYP2C9HRH3
SCHEMBL9924923 0.94 SCN9A (0.35) RAB9ASCN9AKDM1A
SCHEMBL9924902 0.92 RAB9A (0.42) RAB9ACYP2D6CYP3A4CYP2C9HRH3
SCHEMBL9924990 0.92 RAB9A (0.44) RAB9ACYP2D6CYP3A4CYP2C9HRH3
SCHEMBL9924789 0.90 KDM1A (0.37) RAB9ACYP2D6CYP1A2CYP2C19SCN9A
SCHEMBL9924919 0.88 SPHK1 (0.41) RAB9ASCN9AL3MBTL1
SCHEMBL9924922 0.88 RAB9A (0.35) RAB9ASCN9A
SCHEMBL9924914 0.88 RAB9A (0.36) RAB9ACYP2C9HRH3SCN9AKDM1A
SCHEMBL9924954 0.87 CYP2C9 (0.36) RAB9ACYP2C9SCN9AKDM1ALMNA
SCHEMBL9924918 0.87 SCN9A (0.34) SCN9AKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468707-B1 DECAHYDRONAPHTHALENE COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS CONTAINING THE COMPOUNDS, AND LIQUID CRYSTAL DISPLAY DEVICES CONTAINING THE LIQUID CRYSTAL COMPOSITIONS JNC CORP (JP) 2017-08-02 EP disclosed
US-8465674-B2 Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition JNC CORPORATION (JP) 2013-06-18 US disclosed
US-8465674-B2 Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition JNC CORPORATION (JP) 2013-06-18 US disclosed
EP-2468707-A1 DECAHYDRONAPHTHALENE COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS CONTAINING THE COMPOUNDS, AND LIQUID CRYSTAL DISPLAY ELEMENTS CONTAINING THE LIQUID CRYSTAL COMPOSITIONS JNC Corporation (JP) 2012-06-27 EP disclosed
US-20120145959-A1 DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION JNC PETROCHEMICAL CORPORATION (JP) 2012-06-14 US disclosed
US-20120145959-A1 DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION JNC PETROCHEMICAL CORPORATION (JP) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120145959-A1 DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION DCUN1D2, OCIAD1, CPNE4 RAB9A 4571/4885CYP2D6 901/4885CYP3A4 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.